Literature DB >> 11158886

Brain single-photon emission CT studies using 99mTc-HMPAO and 99mTc-ECD early after recanalization by local intraarterial thrombolysis in patients with acute embolic middle cerebral artery occlusion.

K Ogasawara1, A Ogawa, M Ezura, H Konno, M Suzuki, T Yoshimoto.   

Abstract

BACKGROUND AND
PURPOSE: The brain distribution of 9mTc-hexamethylpropyleneamine oxime (HMPAO) correlates with regional brain perfusion, whereas 99mTc-ethyl cysteinate dimer (ECD) reflects not only perfusion but also the metabolic status of brain tissue. We compared 99mTc-ECD single-photon emission CT (SPECT) with 99mTc-HMPAO SPECT early after recanalization by local intraarterial thrombolysis (LIT) in patients with acute embolic middle cerebral artery occlusion. We also assessed the predictive value of 99mTc-HMPAO and 99mTc-ECD SPECT for the development of ischemic brain damage.
METHODS: 99mTc-HMPAO and consecutive 99mTc-ECD SPECT studies were performed in 15 patients within 3 hours of LIT. The two SPECT studies were obtained independently using a subtraction technique. SPECT evaluation was performed using semiquantitative region-of-interest analysis. Noninfarction, infarction, and hemorrhage were identified by follow-up CT or MR imaging.
RESULTS: Forty-five lesions were identified (21 noninfarctions, 19 infarctions, and five hemorrhages). Regardless of 99mTc-HMPAO SPECT findings, lesions showing isoactivity (count rate densities of 0.9 to 1.1 as compared with the contralateral side) on 99mTc-ECD SPECT were salvaged. Lesions with hypoactivity (values < 0.9) on 99mTc-ECD SPECT developed irreversible brain damage. Hemorrhage appeared in lesions with both hyperactivity (values > 1.1) on 99mTc-HMPAO SPECT and hypoactivity on 99mTc-ECD SPECT.
CONCLUSION: The brain distribution of 99mTc-ECD in a reperfused area identified by 99mTc-HMPAO SPECT early after recanalization of acute ischemic stroke is dependent on cerebral tissue viability. By combining 99mTc-ECD and 99mTc-HMPAO SPECT, performed within the first few hours of LIT, it is possible to identify patients at risk for hemorrhagic transformation reliably.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11158886      PMCID: PMC7975552     

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  28 in total

1.  Extraction and retention of technetium-99m-ECD in human brain: dynamic SPECT and oxygen-15-water PET studies.

Authors:  K Ishizu; Y Yonekura; Y Magata; H Okazawa; H Fukuyama; F Tanaka; N Hattori; H Kitano; T Fujita; N Tamaki; J Konishi
Journal:  J Nucl Med       Date:  1996-10       Impact factor: 10.057

2.  The retention mechanism of technetium-99m-HM-PAO: intracellular reaction with glutathione.

Authors:  R D Neirinckx; J F Burke; R C Harrison; A M Forster; A R Andersen; N A Lassen
Journal:  J Cereb Blood Flow Metab       Date:  1988-12       Impact factor: 6.200

3.  Unreliability of rCBF-SPECT in subacute ischemic stroke.

Authors:  M Limburg; E A van Royen
Journal:  Stroke       Date:  1993-07       Impact factor: 7.914

4.  PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism.

Authors:  G J del Zoppo; R T Higashida; A J Furlan; M S Pessin; H A Rowley; M Gent
Journal:  Stroke       Date:  1998-01       Impact factor: 7.914

5.  Treatment of right hemispheric cerebral infarction by hemicraniectomy.

Authors:  J B Delashaw; W C Broaddus; N F Kassell; E C Haley; G A Pendleton; D G Vollmer; W W Maggio; M S Grady
Journal:  Stroke       Date:  1990-06       Impact factor: 7.914

6.  99m technetium-ethyl-cysteinate-dimer single-photon emission CT can predict fatal ischemic brain edema.

Authors:  J Berrouschot; H Barthel; R von Kummer; W H Knapp; S Hesse; D Schneider
Journal:  Stroke       Date:  1998-12       Impact factor: 7.914

Review 7.  Hemorrhagic transformation after cerebral ischemia: mechanisms and incidence.

Authors:  P D Lyden; J A Zivin
Journal:  Cerebrovasc Brain Metab Rev       Date:  1993

8.  Technetium-99m d,l-HM-PAO: a new radiopharmaceutical for SPECT imaging of regional cerebral blood perfusion.

Authors:  R D Neirinckx; L R Canning; I M Piper; D P Nowotnik; R D Pickett; R A Holmes; W A Volkert; A M Forster; P S Weisner; J A Marriott
Journal:  J Nucl Med       Date:  1987-02       Impact factor: 10.057

9.  99mTc-bicisate reliably images CBF in chronic brain diseases but fails to show reflow hyperemia in subacute stroke: report of a multicenter trial of 105 cases comparing 133Xe and 99mTc-bicisate (ECD, neurolite) measured by SPECT on same day.

Authors:  N A Lassen; B Sperling
Journal:  J Cereb Blood Flow Metab       Date:  1994-01       Impact factor: 6.200

10.  Assessment of postischemic reperfusion and diamox activation test in stroke using 99mTc-ECD SPECT.

Authors:  J Nakagawara; J Nakamura; R Takeda; T Okumura; T Seki; K Hayase; K Satoh; K Suematsu
Journal:  J Cereb Blood Flow Metab       Date:  1994-01       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.